Internal Medicine, Hematology · Cleveland, OH
NPI
1831299908
Since 2006
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
9500 Euclid Ave
Cleveland, OH, 44195
Phone (800) 223-2273
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,670
154 services
Medicare patients, 2024
58
Average age 73
Drug cost, 2024
$3.3M
137 prescriptions
Company payments, 2025
$47K
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jaroslaw P Maciejewski was code 99213 (office e&m - established), 56 times for 37 patients. In total Jaroslaw P Maciejewski billed 154 services in 6 codes, and Medicare paid $9,670.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-02-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 56 | 37 | $42.67 | $2,390 |
| 99214 Office E&M - Established | Facility | 46 | 32 | $68.83 | $3,166 |
| 99213 Office E&M - Established | Office | 26 | 16 | $68.11 | $1,771 |
By year: 2022 $9,824 for 175 services; 2023 $8,684 for 143 services; 2024 $9,670 for 154 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jaroslaw P Maciejewski prescribed most often to Medicare patients was Fabhalta (Iptacopan Hcl), with 56 prescriptions and refills. In total Jaroslaw P Maciejewski wrote 137 Medicare prescriptions that cost $3.3M.
Brand drugs: 83 claims; generic drugs: 54 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jaroslaw P Maciejewski $47K ($44K in general payments such as food, travel and fees and $3,042 for research) from 5 companies. The largest payer was Novartis Pharmaceuticals Corporation with $27K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.